175 related articles for article (PubMed ID: 36063962)
1. Spatiotemporally controllable diphtherin transgene system and neoantigen immunotherapy.
He M; Sun Y; Cheng Y; Wang J; Zhang M; Sun R; Hou X; Xu J; He H; Wang H; Yuan Z; Lan M; Zhao Y; Yang Y; Chen X; Gao F
J Control Release; 2023 Mar; 355():538-551. PubMed ID: 36063962
[TBL] [Abstract][Full Text] [Related]
2. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
3. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
[TBL] [Abstract][Full Text] [Related]
4. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.
Wu Y; Feng L
Expert Opin Drug Deliv; 2023 Mar; 20(3):323-333. PubMed ID: 36634017
[TBL] [Abstract][Full Text] [Related]
5. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
6. The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma.
Zhang Y; Lin Z; Wan Y; Cai H; Deng L; Li R
Front Immunol; 2019; 10():2472. PubMed ID: 31749795
[TBL] [Abstract][Full Text] [Related]
7. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
8. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
10. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
[TBL] [Abstract][Full Text] [Related]
11. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
12. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
Chen I; Chen MY; Goedegebuure SP; Gillanders WE
Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
[No Abstract] [Full Text] [Related]
13. Light-switchable diphtherin transgene system combined with losartan for triple negtative breast cancer therapy based on nano drug delivery system.
Cheng Y; Sun R; He M; Zhang M; Hou X; Sun Y; Wang J; Xu J; He H; Wang H; Lan M; Zhao Y; Yang Y; Chen X; Gao F
Int J Pharm; 2022 Apr; 618():121613. PubMed ID: 35217071
[TBL] [Abstract][Full Text] [Related]
14. Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines.
Aguilar-Gurrieri C; Barajas A; Rovirosa C; Ortiz R; Urrea V; de la Iglesia N; Clotet B; Blanco J; Carrillo J
Cancer Immunol Immunother; 2023 Jul; 72(7):2113-2125. PubMed ID: 36820900
[TBL] [Abstract][Full Text] [Related]
15. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy.
Huff AL; Longway G; Mitchell JT; Andaloori L; Davis-Marcisak E; Chen F; Lyman MR; Wang R; Mathew J; Barrett B; Rahman S; Leatherman J; Yarchoan M; Azad NS; Yegnasubramanian S; Kagohara LT; Fertig EJ; Jaffee EM; Armstrong TD; Zaidi N
JCI Insight; 2023 Dec; 8(23):. PubMed ID: 38063199
[TBL] [Abstract][Full Text] [Related]
16. Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land.
Yu G; He X; Li X; Wu Y
Biomed Pharmacother; 2022 Sep; 153():113464. PubMed ID: 36076493
[TBL] [Abstract][Full Text] [Related]
17. Advancing nanotechnology for neoantigen-based cancer theranostics.
Zou J; Zhang Y; Pan Y; Mao Z; Chen X
Chem Soc Rev; 2024 Apr; 53(7):3224-3252. PubMed ID: 38379286
[TBL] [Abstract][Full Text] [Related]
18. Cancer neoantigen: Boosting immunotherapy.
Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
[TBL] [Abstract][Full Text] [Related]
19. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
20. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8
Park KS; Nam J; Son S; Moon JJ
Biomaterials; 2021 Jul; 274():120844. PubMed ID: 33962217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
